STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

RENXF Schedule 13G filing by UBS

UBS reported beneficial ownership of 16.8M shares, representing 5.1% of Renalytix plc in this filing.

FiledFeb 10, 2025
Ownership dateDec 31, 2024
Reported shares16.8M
Reported ownership5.1%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 0
Shared voting power 16.8M
Sole dispositive power 0
Shared dispositive power 16.8M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$0.08as of Feb 10, 2025
Latest tracked price$0.04as of Aug 6, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
UBS
CIK
CIK0001610520
Accession
0001610520-25-000008
Form
Schedule 13G
Open SEC filing View RENXF ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →